Get started
Author

Bo Gao

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
2014 · AOCS Study Group, M Köbel, et al. · British Journal of Cancer · 110
PDF
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors
2021 · Jia Liu, Malinda Itchins, et al. · Lung Cancer · 47
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
2015 · Sharon E. Johnatty, Jonathan P. Tyrer, et al. · Clinical Cancer Research · 37
PDF
Nintedanib—A case of treating concurrent idiopathic pulmonary fibrosis and non‐small cell lung cancer
2022 · Shakti Dabholkar, Bo Gao, et al. · Respirology Case Reports · 14
JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials.
2025 · Xiaohua Wu, Yaqing Chen, et al. · Journal of Clinical Oncology · 12
PDF
Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study.
2024 · John J. Park, Bo Gao, et al. · Journal of Clinical Oncology · 10
PDF
Use of durvalumab in stage III n on‐small ‐cell lung cancer based on eligibility for the PACIFIC study
2023 · Emma Boys, Bo Gao, et al. · Thoracic Cancer · 10
PDF
Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib
2021 · Pei N. Ding, Tara L. Roberts, et al. · Translational Lung Cancer Research · 10
PDF
Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
2024 · Mengzhao Wang, Yan Xu, et al. · Lung Cancer · 9
PDF
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
2017 · Dylan M. Glubb, the AGO Study Group, et al. · Oncotarget · 7
PDF
Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience
2010 · Rachel F DEAR, Bo GAO, et al. · Asia-Pacific Journal of Clinical Oncology · 7
OA15.02 Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
2021 · P. Janne, M. Wang, et al. · Journal of Thoracic Oncology · 6
PDF
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
2025 · Yan Xu, James Chih-Hsin Yang, et al. · Cell Reports Medicine · 5
PDF
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).
2024 · Xiuning Le, Alexander I. Spira, et al. · Journal of Clinical Oncology · 5
PDF
Abstract CT179: Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
2024 · Claire Beecroft, Bo Gao, et al. · Cancer Research · 5
Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.
2023 · James Chih-Hsin Yang, Yan Xu, et al. · Journal of Clinical Oncology · 5
PDF
MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.
2025 · Rebecca Heist, Elaine Shum, et al. · Journal of Clinical Oncology · 3
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
2016 · Clara Inkyung Lee, Amanda Siew Kee Low, et al. · Journal of Clinical Oncology · 1
Dose Optimization, Efficacy, and Safety of Cusp06, a Cadherin-6-directed Antibody-drug Conjugate, in Platinum-resistant Ovarian Cancer
2026 · Roisin O'Cearbhaill, Funda Meric-Bernstam, et al. · International Journal of Gynecological Cancer
572 Preliminary safety, pharmacokinetic and pharmacodynamic analysis from the ongoing RAISIC-1 (relief of acidic immune suppression in cancer): phase 1/2 clinical trial of the GPR65 inhibitor PTT-4256
2025 · Ganessan Kichenadasse, Joe Wei, et al. · Regular and Young Investigator Award Abstracts
PDF
Abstract CT152: FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations
2024 · Xiuning Le, Alexander Spira, et al. · Cancer Research
DNA sequencing and gene-expression profiling assists in making a tissue of origin diagnosis in cancer of unknown primary
2022 · Atara Posner, Owen W.J. Prall, et al. · medRxiv
PDF
P1.04-11 Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing
2018 · M. Barnet, K. Jackson, et al. · Journal of Thoracic Oncology
PDF
Abstract LB-121: Exploring the germ-line contribution to exceptional response to PD-1/PD-L1 inhibition in patients with metastatic non-small-cell lung cancer by whole genome sequencing
2018 · Megan B. Barnet, Katherine J. Jackson, et al. · Cancer Research
471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC
2016 · M. Crumbaker, M. Carlino, et al. · Annals of Oncology
Works count: 26
Citation count: 303
H-index: 9
I10-index: 8
Year
Topic
Type